News
GROUPE LDLC : LDLC GROUP WILL PAY EUR 2.00 PER SHARE AS DIVIDEND FOR FISCAL YEAR 2020-2021
LIMONEST, 24 SEPTEMBER 2021, 5.45 PM
Olivier de la Clergerie, LDLC Group CEO, said: “After several years of significant strategic investment for the LDLC Group and in a context of notable
Valbiotis Consolidates Its Development of Innovative Natural Health Solutions by Integrating the Exploration of Microalgae Produced in New Caledonia, Through an Exclusive Agreement With ADECAL-Technopole and IFREMER
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a French research and development company committed to scientific innovation for preventing and combating of metabolic
Regulators Approve Sensorion’s Amendment to Phase 2 AUDIBLE-S Trial of SENS-401 in Sudden Sensorineural Hearing Loss
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specialising in the development of novel therapies to restore, treat and prevent
STREAMWIDE : H1 2021 earnings: continued increase in earnings and sustained investment
_ EBITDA: €4.3m (up 20%)
EBIT: €2.3m (up 25%)
NET INCOME: €1.9m (up 7%)
NET CASH: €8.6m (up €3.7m)
_
Median Technologies Has Been Confirmed as a Preferred Vendor by one of the Top 3 Pharmaceutical Companies in the World, and Selected to Implement Their Clinical Trial Imaging Strategy on Some Key Oncology Indications
Regulatory News:
Median Technologies (Paris:ALMDT) (ALMDT:PA) announced today that the company has been confirmed as a preferred vendor by one of the Top 3 pharmaceutical companies in the world
BIOCORP und MERCK unterzeichnen Kooperationsvereinbarung auf dem Gebiet des menschlichen Wachstumshormons (HGH)
Aufsichtsrechtliche Meldungen:
BIOCORP (FR0012788065 – ALCOR / PEA/KMU-qualifiziert), ein französisches Unternehmen, das auf die Konzeption, Entwicklung und Herstellung von innovativen
BIOCORP and MERCK Sign a Partnership in the Field of Human Growth Hormone (HGH)
Regulatory News:
BIOCORP (FR0012788065 – ALCOR / Eligible PEA PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, and Merck, a leading
GenSight Biologics Announces Positive Data Safety Monitoring Board Review of PIONEER Phase I/II Clinical Trial of GS030 as Optogenetic Treatment for Retinitis Pigmentosa
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Sensorion And Hearing Care Leader Sonova Sign Strategic Research Collaboration
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotech company specializing in the development of novel therapies to restore, treat, and prevent
Median Technologies Changes the Publication Date of Its H1 2021 Results
Regulatory News:
Median Technologies (ALMDT: PA) will announce its H1 2021 results as well as its Q3 2021 business performance indicators on October 21, 2021 after trading close instead of
Valbiotis Releases its Letter to Shareholders for 2021
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic
Valbiotis veröffentlicht Aktionärsbrief für 2021
Pflichtmitteilung:
Valbiotis (FR0013254851 – ALVAL, PEA/KMU-qualifiziert) (Paris:ALVAL), ein französisches Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher
THERANEXUS AND BEYOND BATTEN DISEASE FOUNDATION (BBDF) WIN US INVESTIGATIONAL NEW DRUG (IND) APPROVAL TO START CLINICAL DEVELOPMENT OF BBDF 101
Lyon, 9 September 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases, and Beyond Batten Disease Foundation (BBDF), announce receipt of
GenSight Biologics Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects Before LUMEVOQ® Treatment in Phase III Trials
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210908006154/en/
Figure 1. BCVA in untreated ND4-LHON patients as a
Sensorion and Cochlear to Begin First Clinical Trial of SENS-401 for Hearing Preservation in Combination With Cochlear Implantation
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology, which specializes in the development of novel therapies to restore, treat and prevent
Valbiotis meldet Abschluss der Rekrutierung für klinische Phase-II-Studie HEART für TOTUM•070 bei Hypercholesterinämie, einem Risikofaktor für kardiovaskuläre Erkrankungen
Pflichtmitteilung:
Valbiotis (FR0013254851 – ALVAL, PEA/SME-fähig), ein französisches Forschungs- und Entwicklungsunternehmen, das sich wissenschaftlichen Innovationen zur Prävention und
Median Technologies Announces Outstanding Performance for its iBiopsy® Lung Cancer Screening CADx1 to Accurately Characterize Malignant vs Benign Lung Nodules Based on a Large-scale Patient Cohort
Regulatory News:
Median Technologies (Paris:ALMDT) (ALMDT:PA) announces outstanding performance based on a large-scale lung cancer screening (LCS) patient cohort to characterize malignant vs
Valbiotis Announces the Completion of Recruitment for the Phase II HEART Clinical Study Conducted With TOTUM•070 in Hypercholesterolemia, a Risk Factor for Cardiovascular Disease
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a French research and development company committed to scientific innovation for preventing and combating metabolic diseases
UK MHRA Grants GenSight Biologics’ LUMEVOQ® Ophthalmic Gene Therapy Promising Innovative Medicine Designation
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
GenSight Biologics Announces Publication of RESTORE Study Data Demonstrating Sustained Efficacy 3 Years After Unilateral Injection of LUMEVOQ®
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210830005575/en/
Figure 1. Evolution of best-corrected visual acuity
MND : Turnover growth of +2% in 2020/2021 - Strong growth and marked improvement in profitability expected in 2021/2022
Turnover growth of +2% in 2020/2021
- €41.0m full-year turnover, in line with targets
- Strong business activity in 2020/2021: Order intake: €90m
- Operational break-even target (adjusted EBITDA)
Median Technologies Appoints Jean-Christophe Montigny as Chief Financial Officer and Member of the Executive Committee
Regulatory News:
Median Technologies (Paris:ALMDT) today announces the appointment of Jean-Christophe Montigny as Chief Financial Officer. He will be a member of Median’s executive committee.
MND : Dubai's Roads and Transport Authority and MND to explore developing new innovative and autonomous urban ropeway
As part of its endeavours to come up with efficient solutions for developing an aerial transport network in Dubai, Dubai's Roads and Transport Authority (RTA) signed a Memorandum of Understanding
PRISMAFLEX INTERNATIONAL : Significant growth in Q1 2021-2022 total sales: EUR 11.4 million (+44% on a like-for-like basis)
Significant points:
- Strong rebound in Print activity (+84%) bringing it almost up to a pre-Covid-19 level. Home Decor activity also confirms its positive momentum, first noted at the beginning
GROUPE LDLC : BUSINESS GROWTH IN Q1 2021/2022
LIMONEST, 22 JULY 2021, 5.45 PM
- CONSOLIDATED REVENUES UP 9.8% TO €163.7M (UP 8.2% AT CONSTANT CONSOLIDATION SCOPE)
- SHARP REBOUND IN BTOB BUSINESS TO €45.7M (UP 49.9%)
- BTOC BUSINESS RESILIENCE AT